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Introduction
As early as 1993, in the “Guideline for the 
Study and Evaluation of Gender Differences 
in the Clinical Evaluation of Drugs” the FDA 
encouraged the participation of women 
in clinical trials and recommended that 
“sponsors should collect gender-related 
data during research and development and 
should analyze the data for gender effects.”1 
However a scan of the literature indicates 
that clinical trials carried out during drug 
development phases have rarely considered 
gender as a stratification parameter in 
therapeutic outcome investigations.  
Evidence supporting gender-specific 
therapeutic outcomes, mainly stems from 
Phase IV post-marketing studies.  The 
gradual but expanding trend towards 
rationalized medicine, is however set to 
change the “one size fits all” paradigm to a 
scenario where specific patient parameters, 
including genetic factors and gender, form 
part of a treatment algorithm which is 
optimized on a patient-per-patient platform.  
This is the basis of personalized medicine.
Gender and drug response
Gender may modify therapeutic drug 
outcomes through pharmacokinetic, 
pharmacodynamic as well as 
pharmacogenetic mechanisms.  From a 
pharmacokinetic aspect, gender differences 
in metabolic enzyme activities is a well-
known phenomenon.  For example, the 
anti-anxiety and sedative drug midazolam, 
as well as verapamil (a calcium channel 
blocker) both show higher bioavailability 
in females than males2,3 due to gender 
specific variations in several CYP450 enzyme 
expression levels; while the selective α2-
adrenergic agonist azepexole shows a higher 
degree of venoconstriction in men than in 
women, despite various non-gender-specific 
single nucleotide polymorphisms (SNPs) in 




The study of the role of genetic polymorphisms in drug responses, is 
now a firmly established field of pharmacology research.  It has robust 
applications in predicting drug effect, and therefore contributes 
to the process of optimum selection of drug and dose for specific 
patients.  Since the last 10 years, the FDA as well as the EMA have 
set up their own pharmacogenomics advisory groups, and have 
flagged an increasing number of medicinal products with specific 
genotyping recommendations in order to reap their greatest benefit.  
The contribution of gender to therapeutic outcomes has long been 
recognised, but recent research suggests that gender influence may not 
only occur via well recognised hormonal pathways, but also via direct 
non-hormone-mediated mechanisms.  This influence may confound 
pharmacogenetic predictors, and gender stratification may therefore 
be an important consideration in pharmacogenetic-based drug trials. 
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Pharmacogenetics and gender
Polymorphic variation in the human genome 
is recognised to contribute to a profound 
effect on the therapeutic and adverse 
effects of several drugs.  Drug outcomes 
may be influenced by variation in genes 
which code for drug receptors, metabolic 
enzymes, membrane transporters, signalling 
molecules or any other proteins which 
influence any aspect of drug mechanisms 
and actions.  For example, polymorphic 
variability in the CYP2D6 gene, may 
influence the outcomes of more than 70 
drugs by modifying their rate of metabolism. 
Fast CYP2D6 metabolisers may not respond 
adequately to CYP2D6 substrates such as 
desipramine and nortriptyline (tricyclic 
antidepressants), carvedilol and metoprolol 
(β-blockers), clozapine (an antipsychotic), 
fleicainide (an anti-arrhythmic), tramadol 
(an opioid analgesic) and others, while slow 
metabolizers may develop toxic effects at 
conventional therapeutic doses. Codeine, 
is a rather special case, since CYP2D6 
contributes to its metabolism to morphine, 
and therefore fast CYP2D6 metabolizers may 
show opioid toxicity with conventional doses 
of codeine.5 
The influence of gender on 
pharmacogenetics has just started to be 
debated in the scientific literature.  Its 
contribution as well as the mechanisms 
through which it exerts it, are complex and 
still not well understood.  
Firstly, gender may exert effects on 
therapeutic outcome, in a manner which 
is independent of pharmacogenetic 
contributions.  For example, multiple 
regression analysis of variability in 
S-oxazapam (an anti-anxiety benzodiazepine 
drug) glucoronidation, attributes about 
35% of variability to presence of the D85Y 
genotype of the hepatically-expressed 
UGT2B15 (UDP Glucuronosyltransferase 2 
Family, Polypeptide B15) gene, while an 
additional 14% is attributed to gender. 
Males expresses generally higher activities 
than females, and presence of D85Y variant 
results in a low activity enzyme.6   Similarly, 
the presence of the [PvuII- / XbaI+] 
haplotype in the ESR1 (oestrogen receptor 
1) gene contributes to a greater post-
atorvastatin HDL increase in women than in 
men; however multiple regression analysis 
suggests that these genotype and gender 
influences operate independently of each 
other. Indeed, a greater post-atorvastatin 
HDL increase can still be identified in a 
non-gender stratified analysis of the ESR1 
[PvuII- / XbaI+] haplotype.7  Torasemide, 
a drug used for the management of 
heart failure, is a substrate for CYP2C9 
metabolism and the SLCO1B1 membrane 
transporter and plasma concentrations 
of the drug depend on the genotypic 
contributions of these genes.  In addition, 
female gender has also been determined 
to be a predictor of higher plasma 
torasemide concentrations.  Factorial ANOVA 
analysis has however indicated that the 
contributions these genes and gender, occur 
independently of each other,8 therefore 
indicating that a separate mechanism must 
be in operation for the gender influence.
Secondly, gender may exert effects 
which operate within a pharmacogenetic 
framework. Since very few known 
pharmacogenetically-relevant gene variants 
are located on any of the sex chromosomes, 
gender-dependent pharmacogenetic 
differences are therefore likely to be due to 
male/female differences in the autosome, 
in transcriptional regulation or in post-
transcriptional changes.   More specifically, 
this may relate to (a) hormonal-dependent 
gene expression alterations, (b) gender-
dependent differences in allelic frequencies 
of specific polymorphisms;  sexually 
dimorphic pharmacogenetic allelic 
frequencies manifest as a gender-dependent 
skewness in the distribution of these 
polymorphisms within a population, and 
therefore may contribute to gender-biased 
therapy outcomes, and (c) physiological 
and/or psychological male/female 
differences which contribute to particular 
behavioural phenotypes, especially in the 
case of drugs which act on the central 
nervous system. Such differences may 
cause the same pharmacogenetic genotype 
to generate what may appear to be a 
different phenotype in males and females, 
but what in reality may be the result of 
an independent separate male/female 
characteristic which modifies the phenotype 
expression of the pharmacogene.  For 
example, males and females may perceive 
pain differently, and therefore a single 
genotype which influences analgesic 
efficacy may have different influences 
in males and females carrying the same 
allele due to this psychological effect.  
Nortriptyline pharmacokinetics are known 
to be strongly influenced by the metabolic 
enzyme CYP2D6, and genotyping of the 
CYP2D6 gene can be used to help provide 
clinical dose optimization.9 However 
female patients carrying the same CYP2D6 
genotype as their male counterparts, may 
require lower doses in order to attain the 
same clinical effect, and this is thought to 
be due to physiological effects of oestrogen 
on the brain.10  The cyclic variations in 
oestrogen secretion may further compound 
these issues. Dorado et al., (2012)11 later 
reported gender-dependent differences 
in CYP2C9-dependent hydroxylation of 
the angiotensin II receptor antagonist 
losartan(an antihypertensive), to its more 
active metabolite E3174, with females 
expressing a higher losartan:E3174 ratio 
than males, post administration of a single 
25mg losartan dose.  However it is not 
clear whether this observation could be 
attributed to differences in male/female 
frequencies of specific CYP2C9 genotypes, 
and whether other confounding factors 
such as bodyweight, were taken into 
consideration in this study. 
Emerging data suggests that several 
classically recognised pharmacogenetic 
genotype/phenotype associations may need 
to be reanalysed in a gender-stratified 
manner, in order to understand the gender 
contribution, and better qualify the 
applicability of such associations to the 
field of personalized medicine.
Gender-dependent gene expression
Evidence for significant gender-dependent 
influences on gene expression is 
accumulating.  Microarray-based work 
on murine RNA expression levels in 
several somatic tissues, revealed several 
thousand genes to exhibit sexually 
dimorphic expression in liver, fat and 
muscle, while several hundred exhibited 
sexually dimorphic expression in brain 
tissue.12,13  Such dimorphic expression has 
also been shown using in vitro generated 
bovine blastocytes, where one third of RNA 
transcripts have been shown to be expressed 
at different levels in males and females.14,15  
This provides evidence to indicate that 
significant male/female differences in 
gene expression, may occur at a very early 
stage in development, and in the absence 
of hormonal influences.  Such events also 
occur in humans.16 The mechanisms by 
which the sex chromosomes impose this 
extensive transcriptional regulation upon 
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Key points
•	 The understanding of genetically-influenced therapeutic outcomes is a critical 
component towards the development and application of personalized medicine.
•	 Gender may influence drug response, not simply through DNA sequences located on 
the sex chromosomes, but more commonly through gender-dependent variability 
present throughout the rest of the genome.
•	 The influence of gender on drug response, may act in isolation of other 
response-determining factors, but more commonly acts within a framework of 
pharmacogenetic determinants.
•	 During both preclinical and clinical drug development phases, there is an increased 
need to address gender as a potential variable in the assessment of therapeutic 
outcomes and adverse reactions.
•	 Prescribers should be aware of drugs which are reported to exhibit a degree of 
gender-dependent outcomes.
autosomal genes are yet unclear. In adult 
humans, gender-dependent gene expression 
has been detected in various tissues, such as 
the brain17,18, salivary glands19, heart20 and 
liver CYP450 enzymes.21  
The cytochrome P450 enzyme CYP1B1 
is expressed at higher transcript levels in 
Caucasian females than males, and this 
effect is not due to CYP1B1 genotype. 
Therefore CYP1B1 substrates, such as 
the chemotherapeutic agents docetaxel, 
epirubicin, capecitabine, paclitaxel, 
gemcitabine and cisplatin may have higher 
rates of metabolism in females.22 Moreover, 
this gender-dependent gene expression 
effect, may co-exist with other CYP1B1 
polymorphisms, creating a phenotype for 
which the genetic contributions are difficult 
to dissect.
Sexually dimorphic allelic distribution
Alcohol provides an excellent example 
of a drug which has a gender-dependent 
pharmacogenetic profile. A study carried 
out in Korean alcoholic patients, found 
alcohol dependence in men to be associated 
with a significantly higher frequency of 
alleles *1/1 of the aldehyde dehydrogenase 
2 gene (ALDH2) and *1/1 of the alcohol 
dehydrogenase gene (ADH2).  However, in 
women, alcohol dependence was associated 
with a significantly higher frequency of a 
different allelic subset, namely ADH2*1/1, 
ALDH2*1/2 and ALDH2*2/2.  Moreover, the 
same study found the µ-opioid receptor 
gene (OPRM1) A118G allele, which is also 
recognised to contribute to a tendency 
towards alcohol dependence, to be present 
at a significantly higher frequency in 
alcohol-dependent females, than alcohol-
dependent males.23 The same research group 
had earlier found naltrexone, a µ-opioid 
receptor antagonist, to be more effective 
against alcohol dependence in patients who 
were genotyped A/G or G/G at the OPRM1 
118 locus, than those whose genotype was 
A/A. This data suggests that naltrexone may 
be more effective in females with alcohol 
dependence, than males.24  
The existence of gender-specific 
allelic frequencies, however, cannot 
always be considered to be independent 
of other variables.  In some genes, sexual 
dimorphic distribution has been shown 
to be dependent on factors such as 
ethnicity.  For example, the genes encoding 
5,10-methylenetetrahydrofolate reductase 
(MTHFR) and thymidylate synthase (TYMS) 
are recognised methotrexate (a drug used 
in the treatment of cancer and autoimmune 
diseases) pharmacogenes.  Specifically, the 
MTHFR C677T and A1298C SNPs, and the 
TYMS 5’UTR [28bp tandem repeat]x and 3’UTR 
[6bp del/ins] polymorphisms are known to 
be important in methotrexate outcomes.  
Inoue et al., (2007)25 identified a statistically 
significant male/female difference between 
the allelic frequency of the TYMS 3’-UTR in 
a Japanese population (p=0.015), but the 
other 3 variants did not appear to exhibit 
any sexual dimorphic distribution.  Moreover 
none of the variants demonstrated sexual 
dimorphism in Caucasians.
Conclusion
Pre-clinical and clinical trial design may 
often mask the effects of gender on drug 
response.  The gender distribution of animals 
and human volunteers used is often not 
amenable to study such effects, and in vitro 
cell-based models are usually considered to 
be sex-less.  The relevance of this variable is 
however now coming to light.  Clinical studies 
need to be carried out in a way that makes 
them sensitive to detect gender-specific 
variations.  Several commonly used drugs have 
been denied this opportunity.   Adrenergic 
β2 receptors, the product of the ADRB2 gene, 
demonstrate a higher ligand sensitivity in 
women, compared to men, and this effect 
may compound known functional ADRB2 gene 
polymorphisms.  Adrenergic β1 blockers such as 
metoprolol and propranolol, are sensitive to 
gender-dependent CYP2D6 metabolic activity. 
Statins also exert different therapeutic 
outcomes in males and females, but there 
is disagreement on the precise underlying 
mechanisms.  Common drug adverse effects, 
such as hypokalaemia, hyponatraemia, 
nausea, vomiting, anti-coagulant induced 
bleeding and antipsychotic drug-induced 
weight gain are also more common in women 
than in men.  Pharmacogenetics contributes 
to several adverse effects but is often unable 
explain the unequal gender-distribution of 
these reactions.26 Clinical studies having 
a gender-sensitive design are required.  
Personalized medicine is a challenging 
target.  A pre-requisite to its application 
is the unravelling and understanding of 
variables that contribute to inter-patient 
differences.  Pharmacogenetics and gender 
are undoubtedly two major candidates.
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